American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 71-79 , January 2008

Model Predictive Control of Erythropoietin Administration in the Anemia of ESRD

  • Adam E. Gaweda, PhD

      Affiliations

    • Division of Nephrology, University of Louisville, Louisville, KY
    • ,
  • Alfred A. Jacobs, MD, PhD

      Affiliations

    • Division of Nephrology, University of Louisville, Louisville, KY
    • ,
  • George R. Aronoff, MD

      Affiliations

    • Division of Nephrology, University of Louisville, Louisville, KY
    • ,
  • Michael E. Brier, PhD

      Affiliations

    • Division of Nephrology, University of Louisville, Louisville, KY
    • Department of Veterans Affairs, Louisville, KY.
    • Corresponding Author InformationAddress correspondence to Michael E. Brier, PhD, University of Louisville, 615 S. Preston St, Louisville, KY 40202.

Received 18 April 2007 ,Accepted 3 October 2007.

References 

  1. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  2. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2006;47(suppl 3):S33–S53
  3. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  4. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  5. Gaweda AE, Jacobs AA, Brier ME, Zurada JM. Pharmacodynamic population analysis in chronic renal failure using artificial neural networks—A comparative study. Neural Networks. 2003;16:841–845
  6. Drüke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  7. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  8. Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ. Protocolized anemia management with erythropoietin in hemodialysis patients: A randomized controlled trial. J Am Soc Nephrol. 2003;14:2654–2661
  9. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: A randomized clinical study. J Am Soc Nephrol. 2005;16:1463–1470
  10. Gaweda AE, Muezzinoglu MK, Aronoff GR, Jacobs AA, Zurada JM, Brier ME. Individualization of pharmacological anemia management using reinforcement learning. Neural Networks. 2005;18:826–834
  11. Martin-Guerrero JD, Camps-Valls G, Soria-Olivas E, Serrano-Lopez AJ, Perez-Ruixo JJ, Jimenez-Torres NV. Dosage individualization of erythropoietin using a profile-dependent support vector regression. IEEE Trans Biomed Eng. 2003;50:1136–1142
  12. Martin Guerrero JD, Olivas ES, Valls GC, Serrano Lopez AJ, Perez Ruixo JJ, Torres NV. Use of neural networks for dosage individualization of erythropoietin in patients with secondary anemia to chronic renal failure. Comput Biol Med. 2003;33:361–373
  13. Bellazzi R. Drug delivery optimization through Bayesian networks: An application to erythropoietin therapy in uremic anemia. Comp Biomed Res. 1993;26:274–293

 Originally published online as doi:10.1053/j.ajkd.2007.10.003 on November 28, 2007.

PII: S0272-6386(07)01353-4

doi: 10.1053/j.ajkd.2007.10.003

American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 71-79 , January 2008

Article Tools

* Image Usage & Resolution